Carolyn S. Ricca

Farnesyltransferase inhibitors block the neurofibromatosis type I (NF1) malignant phenotype.

Ning Yan, Carolyn S. Ricca, Jonathan A. Fletcher et al. · PubMed · 1995 · 112 citations

Tumor Biology, Neuro-oncology, Nf1 Patients +15

Ras farnesylation as a target for novel antitumor agents: Potent and selective farnesyl diphosphate analog inhibitors of farnesyltransferase

Veeraswamy Manne, Carolyn S. Ricca, Johnni Gullo Brown et al. · Drug Development Research · 1995 · 69 citations

Novel Antitumor Agents, Abstract Protein Prenylation, Pharmacotherapy +22

Peptide based P21RAS farnesyl transferase inhibitors: systematic modification of the tetrapeptide CA1A2X motif

Katerina Leftheris, Toni Kline, S. Natarajan et al. · Bioorganic & Medicinal Chemistry Letters · 1994 · 36 citations

Tetrapeptide Ca1a2x Motif, Biochemistry, Natural Sciences +9

Siderochelin, a new ferrous-ion chelating agent produced by Nocardia.

Wen-Chin Liu, Susan Fisher, JERRY Jr. SCOTT WELLS et al. · The Journal of Antibiotics · 1981 · 26 citations · Full text

Design, synthesis, and structure–activity relationships of tetrahydroquinoline-based farnesyltransferase inhibitors

Louis J. Lombardo, Amy Camuso, John K. Clark et al. · Bioorganic & Medicinal Chemistry Letters · 2005 · 22 citations · Full text

Tetrahydroquinoline-based Farnesyltransferase Inhibitors, Medicinal Chemistry, Medicine +3